Each compound—epigallocatechin-3-gallate (EGCG), dihydromyricetin, hesperetin and its derivatives, hesperidin, liquiritigenin, naringenin, and naringin—demonstrates protective effects against liver damage through various mechanisms, including the modulation of signaling pathways like TGF-β1/Smad, PI3K/Akt, and cGAS-STING, ultimately contributing to the attenuation of liver fibrosis and improvement in liver function. The gene discussed is TGFB1; the disease is Hepatic fibrosis.